Stock Analiz

Ocular Therapeutix, Inc. (OCUL) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Ocular Therapeutix’s revenue went from $2M in fiscal 2016 to $52M in fiscal 2025, growth of about 44.5% a year.

Net income in fiscal 2025 was -$266M, a net margin of -511.9%; the best year in this period was 2021 with -$7M.

Over the twelve months to September 30, 2026, revenue was $50M and net income -$327M.

Free cash flow was -$217M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 655% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $2M162017: $2M172018: $2M182019: $4M192020: $17M202021: $44M212022: $51M222023: $58M232024: $64M242025: $52M25$52M
Net income
2016: -$45M162017: -$63M172018: -$60M182019: -$86M192020: -$156M202021: -$7M212022: -$71M222023: -$81M232024: -$194M242025: -$266M25-$266M
Free cash flow
2016: -$36M162017: -$59M172018: -$51M182019: -$80M192020: -$54M202021: -$67M212022: -$63M222023: -$76M232024: -$136M242025: -$217M25-$217M
EPS (diluted)
2016: $-1.80162017: $-2.20172018: $-0.42182019: $-1.91192020: $-2.56202021: $-0.98212022: $-0.97222023: $-1.02232024: $-1.22242025: $-1.4225$-1.42

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$50M$52M$64M$58M$51M$44M$17M$4M$2M$2M$2M
Gross profit$44M$45M$58M$53M$47M$39M$15M$2M$2M$1M$1M
Operating income-$343M-$270M-$172M-$82M-$79M-$78M-$63M-$86M-$59M-$62M-$43M
Net income-$327M-$266M-$194M-$81M-$71M-$7M-$156M-$86M-$60M-$63M-$45M
EPS (diluted)$-1.44$-1.42$-1.22$-1.02$-0.97$-0.98$-2.56$-1.91$-0.42$-2.20$-1.80
R&D$246M$197M$128M$61M$53M$50M$29M$41M$37M$31M$27M
Revenue growth—−18.5%+9.0%+13.5%+18.3%+150.1%+311.7%+112.4%+3.5%+1.9%+7.8%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$253M-$205M-$135M-$70M-$60M-$66M-$54M-$78M-$49M-$50M-$34M
Capital spending-$14M-$12M-$1M-$6M-$4M-$1M-$841000-$2M-$2M-$8M-$2M
Free cash flow-$267M-$217M-$136M-$76M-$63M-$67M-$54M-$80M-$51M-$59M-$36M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$57M$43M$33M$18M$17M$15M$8M$9M$7M$7M$6M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$737M$392M$196M$102M$164M$228M$54M$54M$42M$68M
Debt—$77M$76M$74M$36M$33M$34M$35M$25M$18M$16M
Equity—$654M$315M$91M$35M$88M$76M-$4M$36M$26M$52M
Total assets—$808M$458M$252M$149M$205M$262M$79M$73M$55M$75M
Shares (diluted)226M187M158M86M83M82M61M45M38M29M25M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin87.3%87.4%91.2%91.0%91.2%89.9%88.0%45.0%76.6%76.2%76.5%
Operating margin-680.9%-519.8%-269.6%-141.0%-152.7%-179.3%-361.1%-2029.9%-2970.8%-3220.1%-2296.0%
Net margin-648.6%-511.9%-303.7%-138.1%-137.9%-15.1%-894.3%-2043.3%-3014.0%-3296.2%-2369.0%
FCF margin-530.0%-417.5%-213.4%-130.6%-123.0%-153.4%-312.6%-1888.2%-2568.6%-3053.8%-1903.5%
ROIC—-29.2%-34.7%-39.4%-87.6%-51.1%-45.0%-215.8%-77.0%-110.8%-50.6%
ROE—-40.6%-61.4%-88.6%-200.8%-7.4%-204.5%2379.4%-167.2%-242.4%-86.0%

Frequently asked questions

What is Ocular Therapeutix’s annual revenue?

$52M in fiscal 2025 and $50M over the twelve months to September 30, 2026.

How much profit does Ocular Therapeutix make?

Net income was -$266M in fiscal 2025 (net margin -511.9%).

Is Ocular Therapeutix’s revenue growing?

No: revenue fell 18.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.